A Study of Eltrekibart (LY3041658) in Healthy Participants

A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Formulations of Eltrekibart in Healthy Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07545590

Enrollment

Registered

2026-04-22

Start date

2026-04-21

Completion date

2026-08-01

Last updated

2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants. The study will last about 17 weeks.

Interventions

DRUGLY3041658

Administered SC

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Are overtly healthy as determined by medical evaluation including medical history and physical examination * Have a minimum body weight of 45 kilograms (kg). * Have a body mass index (BMI) within the range of 18.5 to 28.5 kilograms per square meter (kg/m²), inclusive

Exclusion criteria

* Have multiple severe allergies to prescription or nonprescription drugs * Are immunocompromised * Have had any of the following types of infection within 3 months prior to the screening visit: * Serious, that is, requiring hospitalization, or intravenous or equivalent oral antibiotic treatment * Opportunistic infections Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over * Chronic, that is, duration of symptoms, signs, or treatment of 6 weeks or longer, or * Recurring, including, but not limited to: * herpes simplex, * herpes zoster, * recurring cellulitis, or * chronic osteomyelitis. * Are currently pregnant or are intending to become pregnant or to breastfeed at any time in the study or within 16 weeks after receiving the single dose of study intervention.

Design outcomes

Primary

Measure	Time frame
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3041658	Predose on Day 1 up to Day 85
PK: Area Under the Concentration Versus Time Curve From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration AUC(0-tlast) of LY3041658	Predose on Day 1 up to Day 85
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658	Predose on Day 1 up to Day 85

Countries

Singapore

Contacts

STUDY_DIRECTORCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026